All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2019-06-18T10:48:41.000Z

EHA 2019 | What is the clinical value of new drugs in AML?

By Emily Smith, Gert Ossenkoppele
Featured
Gert Ossenkoppele
Jun 18, 2019
Share:

Bookmark this article

At the 24th Congress of the European Hematology Association (EHA), Gert Ossenkoppele from the UMC Amsterdam, Netherlands (NL), talks about the clinical value of new drugs in acute myeloid leukemia (AML).

Prof. Ossenkoppele stated these are exciting times for hematologists working in the AML field. Novel drugs, gilteritinib and quizartinib, were highlighted as potential options to meet an urgent medial of relapsed/refractory AML, as was venetoclax which was described by Prof. Ossenkoppele as "a game changer" in AML. Venetoclax has mostly been tested in unfit, elderly patients with promising data leading to its approval by the US FDA. Prof. Ossenkoppele hopes this will follow soon in Europe.
 
Additionally, new combinations with venetoclax are being investigated and this is expected to change the field of AML treatment "extremely soon".

What is the clinical value of new drugs in AML?

More about...
EHA 2019GilteritinibMidostaurinQuizartinibVenetoclax

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 5 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox